Drugs Associated with Urinary Retention Adverse Reactions: A Joint Analysis of FDA Adverse Event Reporting System and Mendelian Randomization

Abstract

ObjectivesTo explore the association between drugs and urinary retention using the FDA Adverse Event Reporting System (FAERs) database and Mendelian randomization analysis, providing preliminary insights into the underlying mechanisms. MethodsDrug adverse reaction reports from the FAERs database from 2004 to 2023 were obtained, and Mendelian randomization analysis was conducted to further validate the causal relationship between drugs and urinary retention using genetic data provided by the IEU OpenGWAS project. ResultsWe identified 78 drugs associated with urinary retention, including Mirabegron, Tiotropium, Quetiapine, and Amlodipine etc. Mendelian randomization analysis indicated genetic markers (SNPs rs10500326, rs4815689, and rs1216743) of Amlodipine were associated with an increased risk of urinary retention. Sensitivity analysis demonstrated the robustness and reliability of the results. ConclusionThis study identified various drugs associated with urinary retention, particularly Amlodipine. This finding provides new clues for further investigation into the mechanisms of drug effects on bladder function and offers important references for clinical practice. However, further randomized controlled trials are needed to validate these associations and explore deeper mechanisms.